Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price reduced by Bank of America from $30.00 to $28.00 in ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) were down 8.9% during trading on Monday after Bank of America lowered their price target on the stock from $30.00 to $28.00. Bank of ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...

Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...

Analysts at B. Riley dropped their Q2 2025 earnings per share estimates for Denali Therapeutics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) hit a new 52-week low on Tuesday after Oppenheimer lowered their price target on the stock from $50.00 to $42.00. Oppenheimer currently has an ...

XBP Europe Holdings, Inc. (NASDAQ:XBP – Get Free Report) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 43,600 shares, a growth of 40.6% from ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Denali Therapeutics in a ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the company, Marketbeat ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...